Recent Quotes (30 days)

You have no recent quotes
chg | %

Nuvo Research Inc  

(Public, TSE:NRI)   Watch this stock  
Find more results for NRI
-0.05 (-1.20%)
Mar 4 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 4.05 - 4.15
52 week 2.50 - 10.36
Open 4.15
Vol / Avg. 43,966.00/113,754.00
Mkt cap 44.42M
P/E 1.01
Div/yield     -
EPS 4.05
Shares 10.83M
Beta 0.48
Inst. own     -
Jan 30, 2015
Nuvo Research Inc Conference Call to Discuss Topline Results of Phase 2 Study of WF10 for the Treatment of Allergic Rhinitis
Jan 13, 2015
Nuvo Research Inc at EBD Biotech Showcase

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 1653.92% -56.37%
Operating margin 1615.45% -56.67%
EBITD margin - -11.76%
Return on average assets 435.80% -41.42%
Return on average equity 565.29% -61.65%
Employees 79 -
CDP Score - -


7560 Airport Rd Unit 10
+1-905-6736980 (Phone)
+1-905-6731842 (Fax)

Website links


Nuvo Research Inc. is a specialty pharmaceutical company with a diverse portfolio of topical and immunology products. The Company operates two business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group has four commercial products, a pipeline of topical and transdermal proprietary drug delivery (TTDD) products focusing on pain and dermatology and four drug delivery platforms that support the development of patented formulations that deliver actives into or through the skin. The TTDD platforms are multiplexed molecular penetration enhancers, Controlled Heat-Assisted Drug Delivery, Peel and DuraPeel. The TPT Group�s four products include Pennsaid, Pennsaid 2%, the heated lidocaine/tetracaine patch and Pliaglis. The Immunology Group has two commercial products, which include a development program for the treatment of allergic rhinitis and an immune system modulation platform to support treatments for a range of immune system related disorders.

Officers and directors

Daniel H. Chicoine Chairman of the Board, Co-Chief Executive Officer
John C. London President, Co-Chief Executive Officer, Director
Stephen L. Lemieux Chief Financial Officer, Vice President
Henrich R. K. Guntermann M.D. President of Europe and Immunology Group, Director
Bradley S. Galer M.D. President of Pain Group
Age: 52
Katina Loucaides Vice President, General Counsel, Secretary
David A. Copeland Lead Independent Director
Anthony E. Dobranowski Independent Director
Jacques Messier Independent Director
Theodore H. Stanley M.D. Independent Director
Age: 73